Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Regulus Therapeutics stock | $0.8966

Own Regulus Therapeutics stock in just a few minutes.

Fact checked

Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 24 staff and has a trailing 12-month revenue of around USD$5 million.

How to buy shares in Regulus Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Regulus Therapeutics. Find the stock by name or ticker symbol: RGLS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regulus Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.8966, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Regulus Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Regulus Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Regulus Therapeutics share price

Use our graph to track the performance of RGLS stocks over time.

Regulus Therapeutics shares at a glance

Information last updated 2020-11-27.
Latest market closeUSD$0.8966
52-week rangeUSD$0.42 - USD$1.74
50-day moving average USD$0.536
200-day moving average USD$0.6531
Wall St. target priceUSD$1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.43

Buy Regulus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Titan
Titan
$0
Stocks, Bonds
N/A
1%
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Regulus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regulus Therapeutics price performance over time

Historical closes compared with the close of $0.8966 from 2020-12-09

1 week (2021-01-11) N/A
1 month (2020-12-22) -36.41%
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Regulus Therapeutics financials

Revenue TTM USD$5 million
Gross profit TTM USD$-5,517,000
Return on assets TTM -45.03%
Return on equity TTM -507.19%
Profit margin 0%
Book value $0.198
Market capitalisation USD$24.9 million

TTM: trailing 12 months

Shorting Regulus Therapeutics shares

There are currently 932,304 Regulus Therapeutics shares held short by investors – that's known as Regulus Therapeutics's "short interest". This figure is 12.9% up from 826,083 last month.

There are a few different ways that this level of interest in shorting Regulus Therapeutics shares can be evaluated.

Regulus Therapeutics's "short interest ratio" (SIR)

Regulus Therapeutics's "short interest ratio" (SIR) is the quantity of Regulus Therapeutics shares currently shorted divided by the average quantity of Regulus Therapeutics shares traded daily (recently around 515085.08287293). Regulus Therapeutics's SIR currently stands at 1.81. In other words for every 100,000 Regulus Therapeutics shares traded daily on the market, roughly 1810 shares are currently held short.

However Regulus Therapeutics's short interest can also be evaluated against the total number of Regulus Therapeutics shares, or, against the total number of tradable Regulus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regulus Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Regulus Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.028% of the tradable shares (for every 100,000 tradable Regulus Therapeutics shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regulus Therapeutics.

Find out more about how you can short Regulus Therapeutics stock.

Regulus Therapeutics share dividends

We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.

Have Regulus Therapeutics's shares ever split?

Regulus Therapeutics's shares were split on a 1:12 basis on 4 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.

Regulus Therapeutics share price volatility

Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.42 up to $1.74. A popular way to gauge a stock's volatility is its "beta".

RGLS.US volatility(beta: 1.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.9791. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Regulus Therapeutics overview

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site